Top

Published in:

01-12-2020 | Antibiotic | Correspondence

Quantifying the economic cost of antibiotic resistance and the impact of related interventions: rapid methodological review, conceptual framework and recommendations for future studies

Authors: Mark Jit, Dorothy Hui Lin Ng, Nantasit Luangasanatip, Frank Sandmann, Katherine E. Atkins, Julie V. Robotham, Koen B. Pouwels

Published in: BMC Medicine | Issue 1/2020

Abstract

Background

Antibiotic resistance (ABR) poses a major threat to health and economic wellbeing worldwide. Reducing ABR will require government interventions to incentivise antibiotic development, prudent antibiotic use, infection control and deployment of partial substitutes such as rapid diagnostics and vaccines. The scale of such interventions needs to be calibrated to accurate and comprehensive estimates of the economic cost of ABR.

Methods

A conceptual framework for estimating costs attributable to ABR was developed based on previous literature highlighting methodological shortcomings in the field and additional deductive epidemiological and economic reasoning. The framework was supplemented by a rapid methodological review.

Results

The review identified 110 articles quantifying ABR costs. Most were based in high-income countries only (91/110), set in hospitals (95/110), used a healthcare provider or payer perspective (97/110), and used matched cohort approaches to compare costs of patients with antibiotic-resistant infections and antibiotic-susceptible infections (or no infection) (87/110). Better use of methods to correct biases and confounding when making this comparison is needed. Findings also need to be extended beyond their limitations in (1) time (projecting present costs into the future), (2) perspective (from the healthcare sector to entire societies and economies), (3) scope (from individuals to communities and ecosystems), and (4) space (from single sites to countries and the world). Analyses of the impact of interventions need to be extended to examine the impact of the intervention on ABR, rather than considering ABR as an exogeneous factor.

Conclusions

Quantifying the economic cost of resistance will require greater rigour and innovation in the use of existing methods to design studies that accurately collect relevant outcomes and further research into new techniques for capturing broader economic outcomes.

Available only for authorised users

Holmberg SD, Solomon SL, Blake PA. Health and economic impacts of antimicrobial resistance. Rev Infect Dis. 1987;9:1065–78. https://doi.org/10.1093/clinids/9.6.1065.CrossRefPubMed

Coast J, Smith RD, Millar MR. Superbugs: should antimicrobial resistance be included as a cost in economic evaluation? Health Econ. 1996;5:217–26. https://doi.org/10.1002/(SICI)1099-1050(199605)5:3<217::AID-HEC200>3.0.CO;2-S.CrossRefPubMed

Laxminarayan R, Brown GM. Economics of antibiotic resistance: a theory of optimal use. J Environ Econ Manage. 2001;42:183–206. https://doi.org/10.1006/JEEM.2000.1156.CrossRef

World Health Organization. Global action plan on antimicrobial resistance. Geneva: World Health Organization; 2015. https://apps.who.int/iris/handle/10665/193736.

O’Neill J. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. Review on antimicrobial resistance. London: Wellcome Trust; 2014.

ECDC/EMEA Joint Working Group. The bacterial challenge: time to react. Stockholm: ECDC/EMEA; 2009.

The World Bank. Drug-resistant infections: A threat to our economic future. Washington, DC: World Bank; 2017.CrossRef

Colman AM, Krockow EM, Chattoe-Brown E, Tarrant C. Medical prescribing and antibiotic resistance: a game-theoretic analysis of a potentially catastrophic social dilemma. PLoS One. 2019;14:e0215480. https://doi.org/10.1371/journal.pone.0215480.CrossRefPubMedPubMedCentral

Smith RD, Yago M, Millar M, Coast J. A macroeconomic approach to evaluating policies to contain antimicrobial resistance. Appl Health Econ Health Policy. 2006;5:55–65. https://doi.org/10.2165/00148365-200605010-00007.CrossRefPubMed

10.

Roope LSJ, Smith RD, Pouwels KB, Buchanan J, Abel L, Eibich P, et al. The challenge of antimicrobial resistance: what economics can contribute. Science. 2019;364:eaau4679. https://doi.org/10.1126/science.aau4679.CrossRefPubMed

11.

Cohen B, Larson EL, Stone PW, Neidell M, Glied SA. Factors associated with variation in estimates of the cost of resistant infections. Med Care. 2010;48:767–75. https://doi.org/10.1097/MLR.0b013e3181e358b9.CrossRefPubMed

12.

Wilton P, Smith R, Coast J, Millar M. Strategies to contain the emergence of antimicrobial resistance: a systematic review of effectiveness and cost-effectiveness. J Health Serv Res Policy. 2002;7:111–7. https://doi.org/10.1258/1355819021927764.CrossRefPubMed

13.

Smith RD, Coast J. The economic burden of antimicrobial resistance: why it is more serious than current studies suggest. Technical report. London: London School of Hygiene & Tropical Medicine; 2012. https://doi.org/10.17037/PUBS.00639028.CrossRef

14.

Naylor NR, Atun R, Zhu N, Kulasabanathan K, Silva S, Chatterjee A, et al. Estimating the burden of antimicrobial resistance: a systematic literature review. Antimicrob Resist Infect Control. 2018;7:58. https://doi.org/10.1186/s13756-018-0336-y.CrossRefPubMedPubMedCentral

15.

Founou RC, Founou LL, Essack SY. Clinical and economic impact of antibiotic resistance in developing countries: a systematic review and meta-analysis. PLoS One. 2017;12:e0189621. https://doi.org/10.1371/journal.pone.0189621.CrossRefPubMedPubMedCentral

16.

Smith R, Coast J. The true cost of antimicrobial resistance. BMJ Br Med J. 2013;346:1–5. https://doi.org/10.1136/bmj.f1493.CrossRef

17.

Gandra S, Barter DM, Laxminarayan R. Economic burden of antibiotic resistance: how much do we really know? Clin Microbiol Infect. 2014;20:973–80. https://doi.org/10.1111/1469-0691.12798.CrossRefPubMed

18.

Antonanzas F, Lozano C, Torres C. Economic features of antibiotic resistance: the case of methicillin-resistant Staphylococcus aureus. Pharmacoeconomics. 2015;33:285–325. https://doi.org/10.1007/s40273-014-0242-y.CrossRefPubMed

19.

KPMG LLP. The global economic impact of anti-microbial resistance. 2014. www.kpmg.com/uk/economicoutlook. Accessed 1 Dec 2018.

20.

Taylor J, Hafner M, Yerushalmi E, Smith R, Bellasio J, Vardavas R, et al. Estimating the economic costs of antimicrobial resistance: model and results: RAND Europe; 2014. https://www.rand.org/pubs/research_reports/RR911.html. Accessed 30 Jan 2020

21.

de Kraker MEA, Stewardson AJ, Harbarth S. Will 10 million people die a year due to antimicrobial resistance by 2050? PLoS Med. 2016;13:e1002184. https://doi.org/10.1371/journal.pmed.1002184.CrossRefPubMedPubMedCentral

22.

Howard D, Cordell R, McGowan JE, Packard RM, Scott RD, Solomon SL, et al. Measuring the economic costs of antimicrobial resistance in hospital settings: summary of the Centers for Disease Control and Prevention-Emory workshop. Clin Infect Dis. 2001;33:1573–8. https://doi.org/10.1086/323758.CrossRefPubMed

23.

Kaier K, Heister T. Appropriate analysis of the additional costs of antibiotic resistance: the impact of different biases. Value Health. 2016;19:A366–7. https://doi.org/10.1016/j.jval.2016.09.118.CrossRef

24.

Spieker A, Roy J, Mitra N. Analyzing medical costs with time-dependent treatment: the nested g-formula. Health Econ. 2018;27:1063–73. https://doi.org/10.1002/hec.3651.CrossRefPubMed

25.

Pouwels KB, Vansteelandt S, Batra R, Edgeworth JD, Smieszek T, Robotham JV. Intensive care unit (ICU)-acquired bacteraemia and ICU mortality and discharge: addressing time-varying confounding using appropriate methodology. J Hosp Infect. 2018;99:42–7. https://doi.org/10.1016/J.JHIN.2017.11.011.CrossRefPubMed

26.

Gregori D, Petrinco M, Bo S, Desideri A, Merletti F, Pagano E. Regression models for analyzing costs and their determinants in health care: an introductory review. Int J Qual Health Care. 2011;23:331–41. https://doi.org/10.1093/intqhc/mzr010.CrossRefPubMed

27.

Chisholm D, Stanciole AE, Tan Torres Edejer T, Evans DB. Economic impact of disease and injury: counting what matters. BMJ. 2010;340:c924. https://doi.org/10.1136/bmj.c924.CrossRefPubMed

28.

Sandmann FG, Robotham JV, Deeny SR, Edmunds WJ, Jit M. Estimating the opportunity costs of bed-days. Health Econ. 2018;27:592–605.CrossRef

29.

Naylor NR, Pouwels KB, Hope R, Green N, Henderson KL, Knight GM, et al. The health and cost burden of antibiotic resistant and susceptible Escherichia coli bacteraemia in the English hospital setting: A national retrospective cohort study. PLoS One. 2019;14:e0221944. https://doi.org/10.1371/journal.pone.0221944.CrossRefPubMedPubMedCentral

30.

Molton JS, Tambyah PA, Ang BSP, Ling ML, Fisher DA. The global spread of healthcare-associated multidrug-resistant bacteria: a perspective from Asia. Clin Infect Dis. 2013;56:1310–8. https://doi.org/10.1093/cid/cit020.CrossRefPubMed

31.

Alvarez-Uria G, Gandra S, Mandal S, Laxminarayan R. Global forecast of antimicrobial resistance in invasive isolates of Escherichia coli and Klebsiella pneumoniae. Int J Infect Dis. 2018;68:50–3. https://doi.org/10.1016/j.ijid.2018.01.011.CrossRefPubMedPubMedCentral

32.

de Kraker MEA, Davey PG, Grundmann H, on behalf of the BURDEN study group. Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in Europe. PLoS Med. 2011;8:e1001104. https://doi.org/10.1371/journal.pmed.1001104.CrossRefPubMedPubMedCentral

33.

Reynolds CA, Finkelstein JA, Ray GT, Moore MR, Huang SS. Attributable healthcare utilization and cost of pneumonia due to drug-resistant streptococcus pneumonia: a cost analysis. Antimicrob Resist Infect Control. 2014;3:16. https://doi.org/10.1186/2047-2994-3-16.CrossRefPubMedPubMedCentral

34.

Teillant A, Gandra S, Barter D, Morgan DJ, Laxminarayan R. Potential burden of antibiotic resistance on surgery and cancer chemotherapy antibiotic prophylaxis in the USA: a literature review and modelling study. Lancet Infect Dis. 2015;15:1429–37. https://doi.org/10.1016/S1473-3099(15)00270-4.CrossRefPubMed

35.

Alsan M, Schoemaker L, Eggleston K, Kammili N, Kolli P, Bhattacharya J. Out-of-pocket health expenditures and antimicrobial resistance in low-income and middle-income countries: an economic analysis. Lancet Infect Dis. 2015;15:1203–10. https://doi.org/10.1016/S1473-3099(15)00149-8.CrossRefPubMedPubMedCentral

36.

Coast J, Smith RD, Millar MR. An economic perspective on policy to reduce antimicrobial resistance. Soc Sci Med. 1998;46:29–38. https://doi.org/10.1016/S0277-9536(97)00132-9.CrossRefPubMed

37.

Phelps CE. Bug/drug resistance. Sometimes less is more. Med Care. 1989;27:194–203.CrossRef

38.

de Vries LM, van Baal PHM, Brouwer WBF. Future costs in cost-effectiveness analyses: past, present, future. Pharmacoeconomics. 2019;37:119–30. https://doi.org/10.1007/s40273-018-0749-8.CrossRefPubMed

39.

Smith RD, Yago M, Millar M, Coast J. Assessing the macroeconomic impact of a healthcare problem: the application of computable general equilibrium analysis to antimicrobial resistance. J Health Econ. 2005;24:1055–75. https://doi.org/10.1016/J.JHEALECO.2005.02.003.CrossRefPubMed

40.

Howard DH. Resistance-induced antibiotic substitution. Health Econ. 2004;13:585–95. https://doi.org/10.1002/hec.856.CrossRefPubMed

41.

Le Doare K, O’Driscoll M, Turner K, Seedat F, Russell NJ, Seale AC, et al. Intrapartum antibiotic chemoprophylaxis policies for the prevention of group B streptococcal disease worldwide: systematic review. Clin Infect Dis. 2017;65(Suppl_2):S143–51. https://doi.org/10.1093/cid/cix654.CrossRefPubMedPubMedCentral

42.

Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Surg Infect. 2013;14:73–156. https://doi.org/10.1089/sur.2013.9999.CrossRef

43.

Hübner C, Hübner N-O, Hopert K, Maletzki S, Flessa S. Analysis of MRSA-attributed costs of hospitalized patients in Germany. Eur J Clin Microbiol Infect Dis. 2014;33:1817–22. https://doi.org/10.1007/s10096-014-2131-x.CrossRefPubMed

44.

Rudholm N. Economic implications of antibiotic resistance in a global economy. J Health Econ. 2002;21:1071–83.CrossRef

45.

Chen H-H, Stringer A, Eguale T, Rao GG, Ozawa S. Impact of antibiotic resistance on treatment of pneumococcal disease in Ethiopia: an agent-based modeling simulation. Am J Trop Med Hyg. 2019;101:1042–53. https://doi.org/10.4269/ajtmh.18-0930.CrossRefPubMed

46.

Chesson HW, Kirkcaldy RD, Gift TL, Owusu-Edusei K, Weinstock HS. An illustration of the potential health and economic benefits of combating antibiotic-resistant gonorrhea. Sex Transm Dis. 2018;45:250–3. https://doi.org/10.1097/OLQ.0000000000000725.CrossRefPubMedPubMedCentral

47.

Elbasha EH. Deadweight loss of bacterial resistance due to overtreatment. Health Econ. 2003;12:125–38. https://doi.org/10.1002/hec.702.CrossRefPubMed

48.

Johnston KJ, Thorpe KE, Jacob JT, Murphy DJ. The incremental cost of infections associated with multidrug-resistant organisms in the inpatient hospital setting – a national estimate. Health Serv Res. 2019;54:782–92. https://doi.org/10.1111/1475-6773.13135.CrossRefPubMed

49.

Lee BY, Singh A, David MZ, Bartsch SM, Slayton RB, Huang SS, et al. The economic burden of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA). Clin Microbiol Infect. 2013;19:528–36. https://doi.org/10.1111/j.1469-0691.2012.03914.x.CrossRefPubMed

50.

Michaelidis CI, Fine MJ, Lin CJ, Linder JA, Nowalk MP, Shields RK, et al. The hidden societal cost of antibiotic resistance per antibiotic prescribed in the United States: an exploratory analysis. BMC Infect Dis. 2016;16:655. https://doi.org/10.1186/s12879-016-1990-4.CrossRefPubMedPubMedCentral

51.

Phodha T, Riewpaiboon A, Malathum K, Coyte PC. Excess annual economic burdens from nosocomial infections caused by multi-drug resistant bacteria in Thailand. Expert Rev Pharmacoecon Outcomes Res. 2019;19:305–12. https://doi.org/10.1080/14737167.2019.1537123.CrossRefPubMed

52.

Shrestha P, Cooper BS, Coast J, Oppong R, Do Thi Thuy N, Phodha T, et al. Enumerating the economic cost of antimicrobial resistance per antibiotic consumed to inform the evaluation of interventions affecting their use. Antimicrob Resist Infect Control. 2018;7:98. https://doi.org/10.1186/s13756-018-0384-3.CrossRefPubMedPubMedCentral

53.

Thorpe KE, Joski P, Johnston KJ. Antibiotic-resistant infection treatment costs have doubled since 2002, now exceeding $2 billion annually. Health Aff. 2018;37:662–9. https://doi.org/10.1377/hlthaff.2017.1153.CrossRef

54.

Tillekeratne LG, Bodinayake C, Nagahawatte A, Kurukulasooriya R, Orlando LA, Simmons RA, et al. Use of clinical algorithms and rapid influenza testing to manage influenza-like illness: a cost-effectiveness analysis in Sri Lanka. BMJ Glob Health. 2019;4:e001291. https://doi.org/10.1136/bmjgh-2018-001291.CrossRefPubMedPubMedCentral

55.

Touat M, Opatowski M, Brun-Buisson C, Cosker K, Guillemot D, Salomon J, et al. A payer perspective of the hospital inpatient additional care costs of antimicrobial resistance in France: a matched case–control study. Appl Health Econ Health Policy. 2019;17:381–9. https://doi.org/10.1007/s40258-018-0451-1.CrossRefPubMed

56.

U.S. Congress, Office of Technology Assessment. Impacts of Antibiotic-Resistant Bacteria, OTA-H-629. Washington, DC: U.S. Government Printing Office; 1995. https://ota.fas.org/reports/9503.pdf.

57.

Zhen X, Li Y, Chen Y, Dong P, Liu S, Dong H. Effect of multiple drug resistance on total medical costs among patients with intra-abdominal infections in China. PLoS One. 2018;13:e0193977. https://doi.org/10.1371/journal.pone.0193977.CrossRefPubMedPubMedCentral

58.

Högberg LD, Muller A, Zorzet A, Monnet DL, Cars O. Antibiotic use worldwide. Lancet Infect Dis. 2014;14:1179–80. https://doi.org/10.1016/S1473-3099(14)70987-9.CrossRefPubMed

59.

Pouwels KB, Chatterjee A, Cooper BS, Robotham JV. Antibiotic resistance, stewardship, and consumption. Lancet Planet Health. 2019;3:e66. https://doi.org/10.1016/S2542-5196(18)30283-3.CrossRefPubMed

60.

Asche C, McAdam-Marx C, Seal B, Crookston B, Mullins CD. Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance. J Antimicrob Chemother. 2008;61:1162–8. https://doi.org/10.1093/jac/dkn073.CrossRefPubMed

61.

Chesson H, Owusu-Edusei K, Kirkcaldy RD, Gift TL, Weinstock HS. P5.096 Estimating the potential economic impact of antimicrobial resistance in Neisseria gonorrhoeae in the United States. Sex Transm Infect. 2013;89(Suppl 1):A365. https://doi.org/10.1136/sextrans-2013-051184.1140.CrossRef

62.

Roy K, Wang SA, Meltzer MI. Optimizing treatment of antimicrobial-resistant Neisseria gonorrhoeae. Emerg Infect Dis. 2005;11:1265–73. https://doi.org/10.3201/eid1108.050157.CrossRefPubMedPubMedCentral

63.

Elliott RA, Weatherly HLA, Hawkins NS, Cranny G, Chambers D, Myers L, et al. An economic model for the prevention of MRSA infections after surgery: non-glycopeptide or glycopeptide antibiotic prophylaxis? Eur J Health Econ. 2010;11:57–66. https://doi.org/10.1007/s10198-009-0175-0.CrossRefPubMed

64.

Ruiz-Ramos J, Frasquet J, Romá E, Poveda-Andres JL, Salavert-Leti M, Castellanos A, et al. Cost-effectiveness analysis of implementing an antimicrobial stewardship program in critical care units. J Med Econ. 2017;20:652–9. https://doi.org/10.1080/13696998.2017.1311903.CrossRefPubMed

65.

Oppong R, Smith RD, Little P, Verheij T, Butler CC, Goossens H, et al. Cost effectiveness of amoxicillin for lower respiratory tract infections in primary care: an economic evaluation accounting for the cost of antimicrobial resistance. Br J Gen Pract. 2016;66:e633–9. https://doi.org/10.3399/bjgp16X686533.CrossRefPubMedPubMedCentral

66.

Kaier K, Frank U. Measuring the externality of antibacterial use from promoting antimicrobial resistance. Pharmacoeconomics. 2010;28:1123–8. https://doi.org/10.2165/11535640-000000000-00000.CrossRefPubMed

67.

Kaier K. Economic implications of the dynamic relationship between antibiotic use and hospital-acquired infections. Value Health. 2012;15:87–93. https://doi.org/10.1016/J.JVAL.2011.09.005.CrossRefPubMed

68.

Kaier K. Economic modeling of the persistence of antimicrobial resistance. Nat Resour Model. 2012;25:388–402. https://doi.org/10.1111/j.1939-7445.2011.00114.x.CrossRef

69.

Pouwels KB, Muller-Pebody B, Smieszek T, Hopkins S, Robotham JV. Selection and co-selection of antibiotic resistances among Escherichia coli by antibiotic use in primary care: an ecological analysis. PLoS One. 2019;14:e0218134. https://doi.org/10.1371/journal.pone.0218134.CrossRefPubMedPubMedCentral

70.

Pouwels KB, Freeman R, Muller-Pebody B, Rooney G, Henderson KL, Robotham JV, et al. Association between use of different antibiotics and trimethoprim resistance: going beyond the obvious crude association. J Antimicrob Chemother. 2018;73:1700–7. https://doi.org/10.1093/jac/dky031.CrossRefPubMed

71.

Pouwels KB, Butler CC, Robotham JV. Comment on “The distribution of antibiotic use and its association with antibiotic resistance.”. eLife. 2019;8. https://doi.org/10.7554/eLife.46561.

72.

Coast J, Smith R, Karcher A-M, Wilton P, Millar M. Superbugs II: how should economic evaluation be conducted for interventions which aim to contain antimicrobial resistance? Health Econ. 2002;11:637–47. https://doi.org/10.1002/hec.693.CrossRefPubMed

73.

Livermore DM. The 2018 Garrod lecture: preparing for the black swans of resistance. J Antimicrob Chemother. 2018;73:2907–15. https://doi.org/10.1093/jac/dky265.CrossRefPubMed

74.

Goossens H, Ferech M, Vander Stichele R, Elseviers M. ESAC project group. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet. 2005;365:579–87. https://doi.org/10.1016/S0140-6736(05)17907-0.CrossRefPubMed

75.

Lehtinen S, Blanquart F, Croucher NJ, Turner P, Lipsitch M, Fraser C. Evolution of antibiotic resistance is linked to any genetic mechanism affecting bacterial duration of carriage. Proc Natl Acad Sci U S A. 2017;114:1075–80. https://doi.org/10.1073/pnas.1617849114.CrossRefPubMedPubMedCentral

76.

Davies NG, Flasche S, Jit M, Atkins KE. Within-host dynamics shape antibiotic resistance in commensal bacteria. Nat Ecol Evol. 2019;3:440–9. https://doi.org/10.1038/s41559-018-0786-x.CrossRefPubMedPubMedCentral

77.

López-Lozano J-M, Lawes T, Nebot C, Beyaert A, Bertrand X, Hocquet D, et al. A nonlinear time-series analysis approach to identify thresholds in associations between population antibiotic use and rates of resistance. Nat Microbiol. 2019;4:1160–72. https://doi.org/10.1038/s41564-019-0410-0.CrossRefPubMed

78.

Jansen JP, Kumar R, Carmeli Y. Cost-effectiveness evaluation of ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections accounting for antibiotic resistance. Value Health. 2009;12:234–44 https://www.sciencedirect.com/science/article/pii/S1098301510607000. Accessed 26 Dec 2018.CrossRef

79.

Haeussler K, van den Hout A, Baio G. A dynamic Bayesian Markov model for health economic evaluations of interventions in infectious disease. BMC Med Res Methodol. 2018;18:82. https://doi.org/10.1186/s12874-018-0541-7.CrossRefPubMedPubMedCentral

80.

Brown G, Layton DF. Resistance economics: social cost and the evolution of antibiotic resistance. Environ Dev Econ. 1996;1:349–55. https://doi.org/10.1017/S1355770X0000067X.CrossRef

81.

Andersson DI, Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol. 2010;8:260–71. https://doi.org/10.1038/nrmicro2319.CrossRefPubMed

82.

Greenhalgh T, Thorne S, Malterud K. Time to challenge the spurious hierarchy of systematic over narrative reviews? Eur J Clin Investig. 2018;48:e12931. https://doi.org/10.1111/eci.12931.CrossRef

Title: Quantifying the economic cost of antibiotic resistance and the impact of related interventions: rapid methodological review, conceptual framework and recommendations for future studies
Authors: Mark Jit
Dorothy Hui Lin Ng
Nantasit Luangasanatip
Frank Sandmann
Katherine E. Atkins
Julie V. Robotham
Koen B. Pouwels
Publication date: 01-12-2020
Publisher: BioMed Central
Keyword: Antibiotic
Published in: BMC Medicine / Issue 1/2020
Electronic ISSN: 1741-7015
DOI: https://doi.org/10.1186/s12916-020-1507-2

At a glance: The STEP trials

Springer Medicine

Quantifying the economic cost of antibiotic resistance and the impact of related interventions: rapid methodological review, conceptual framework and recommendations for future studies

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

Correction to: The comorbidity burden of type 2 diabetes mellitus: patterns, clusters and predictions from a large English primary care cohort

Lifestyle factors and risk of multimorbidity of cancer and cardiometabolic diseases: a multinational cohort study

Mutations in normal tissues—some diagnostic and clinical implications

Mental, behavioral and neurodevelopmental disorders in the ICD-11: an international perspective on key changes and controversies

The practice of evaluating epidemic response in humanitarian and low-income settings: a systematic review

Are environmental area characteristics at birth associated with overweight and obesity in school-aged children? Findings from the SLOPE (Studying Lifecourse Obesity PrEdictors) population-based cohort in the south of England